sorafenib has been researched along with pd 184352 in 13 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pd 184352) | Trials (pd 184352) | Recent Studies (post-2010) (pd 184352) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 185 | 3 | 74 |
Protein | Taxonomy | sorafenib (IC50) | pd 184352 (IC50) |
---|---|---|---|
RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | 0.012 | |
Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | 0.0263 | |
Casein kinase II subunit alpha | Homo sapiens (human) | 0.017 | |
Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | 0.0218 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (46.15) | 29.6817 |
2010's | 5 (38.46) | 24.3611 |
2020's | 2 (15.38) | 2.80 |
Authors | Studies |
---|---|
Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Bharate, SB; Raghuvanshi, R | 1 |
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A | 1 |
Beeram, M; Patnaik, A | 1 |
Götz, R; Kramer, BW; Rapp, UR | 1 |
Arslan, MA; Basaga, H; Kutuk, O | 1 |
Adjei, AA | 1 |
Cheng, AL; Fan, HH; Hsu, C; Liang, JD; Liou, JY; Lu, YS; Ou, DL; Shen, YC; Wang, DS; Yu, SL | 1 |
Dent, P; Fisher, RI; Friedberg, J; Grant, S; Jordan, N; Nguyen, TK | 1 |
Bertolotto, C; Bourcier, C; Grépin, R; Griseri, P; Mazure, N; Pagès, G | 1 |
Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG | 1 |
4 review(s) available for sorafenib and pd 184352
Article | Year |
---|---|
Kinase Inhibitors as Underexplored Antiviral Agents.
Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses | 2022 |
Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.
Topics: Adult; Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Child; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Structure; Neoplasm Proteins; Neoplasms; Niacinamide; Oligodeoxyribonucleotides, Antisense; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Thionucleotides; Xenograft Model Antitumor Assays | 2002 |
Protein kinases as drug targets in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzenesulfonates; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Trastuzumab | 2006 |
K-ras as a target for lung cancer therapy.
Topics: Benzamides; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sensitivity and Specificity; Sorafenib; Survival Analysis; Treatment Outcome | 2008 |
9 other study(ies) available for sorafenib and pd 184352
Article | Year |
---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
Topics: Adenoma; Animals; Apoptosis; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Division; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2004 |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Membrane Proteins; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins; Pyridines; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured | 2009 |
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma, Large B-Cell, Diffuse; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Transfection | 2010 |
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL5; Dichlororibofuranosylbenzimidazole; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Genes, Reporter; Half-Life; Humans; Immunotherapy, Active; Interleukin-8; Leupeptins; MAP Kinase Kinase Kinases; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyridines; Receptors, Interleukin-8B; RNA Stability; RNA, Messenger; RNA, Small Interfering; Sorafenib; Transfection; Tristetraprolin; Tumor Cells, Cultured; Vaccination | 2011 |
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Dogs; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |